|
|
 |
|
Viewing report
|
|
|
|
Combating Generics: Counter-Generics Strategy, Tactics and Execution
Cutting Edge Information, Nov 2007, Pages: 159
Protect brand revenues with a multi-tiered counter-generics strategy:
Generic drugs now account for more than 60% of all prescriptions filled in the US, and more than $60 billion worth of drugs face US patent expiration by 2011.
Use this report to build a counter-generics strategy that includes long-term, R&D-based lifecycle planning (such as new formulations and next-generation drugs) as well as frontline tactics (such as litigation and counter-promotion) -- and understand how companies launch authorized generics and attempt OTC switches
Explore primary data for a comprehensive look at current counter-generics defense:
- Investigate strategies, investments and results for seven brands
- Benchmark your efforts against timelines, investment levels, and past-and-future use of critical lifecycle management and counter-generics options:
New formulation launches
Defensive pricing changes
Counter-promotion
Approval for new indications
Next-generation product launches
Patent litigation
Authorized generics negotiations
Launches through generics subsidiaries
Pediatric trials and six-month exclusivity
OTC switching
- Compare headcounts dedicated to counter-generics preparation over the life of a brand
Metrics Introduction
Combating Generics: Counter-Generics Strategy, Tactics and Execution contains more than 450 metrics and 60 charts and graphics. Included among the metrics and charts are:
- Counter-generics investments, tactics and results for seven blinded brands
- Survey data detailing implementation timelines, investment levels, recent use and planned future use for the following options:
- Launch of new formulations
- Use of pricing to maintain competitiveness
- Counter-promotion in anticipation of generics
- Approval for new indications
- Next-generation product launches
- Patent litigation and citizen petitions
- Authorized generics negotations
- Launches through generics subsidiaries
- Pediatric exclusivity
- Rx-to-OTC switching
- Counter-generics staffing headcounts by lifecycle stage
- Functional involvement in counter-generics and lifecycle planning
- Comparisons of trends between new counter-generics data and data collected in past surveys
- Sales data for and analysis of steps taken by high-profile drugs facing generic competition
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Generics in Japan
Generics Series: Authorized Generics Analysis
Global Generics Industry Report
Generics Defense Strategies: Effective Brand Protection through Patent, Formulation, OTC and DTC Strategies
Practical Defense Strategies for Combating Generics Competition
Generics Series: Key trends and events in the 7 major markets
New Dynamics and Challenges in the Generics Market 2007
Generics: Global Industry Guide
Authorized Generics: Look Before you Leap
Global Generics Guide 3rd Edition: Benchmarking Generics Company Capabilities and Strategy
Generics Series: Generics Trends in the Seven Major Markets and Beyond
Blockbuster Patent Expirations and the Future of the Generics Market
|
|
|
|
